Request Demo
Last update 20 Mar 2025
LCAR-AIO(Legend Biotech)
Last update 20 Mar 2025
Overview
Basic Info
Drug Type CAR-T |
Synonyms LCAR-AIO Cells, Lcaraio |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD20 modulators(B-lymphocyte antigen CD20 modulators), CD22 modulators(CD22 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with LCAR-AIO(Legend Biotech)NCT06869278
An Open Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
NCT06866080
An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LCAR-AIO for the Treatment of Relapsed/Refractory Autoimmune Diseases (r/r AID)
NCT06653556
An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LCAR-AIO for the Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)
100 Clinical Results associated with LCAR-AIO(Legend Biotech)
Login to view more data
100 Translational Medicine associated with LCAR-AIO(Legend Biotech)
Login to view more data
100 Patents (Medical) associated with LCAR-AIO(Legend Biotech)
Login to view more data
100 Deals associated with LCAR-AIO(Legend Biotech)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Sclerosis | Phase 1 | China | 15 Mar 2025 | |
| Myasthenia Gravis | Phase 1 | China | 15 Mar 2025 | |
| Myelin oligodendrocyte glycoprotein antibody-associated disease | Phase 1 | China | 15 Mar 2025 | |
| Neuromyelitis Optica | Phase 1 | China | 15 Mar 2025 | |
| Systemic Lupus Erythematosus | Phase 1 | China | 08 Jan 2025 | |
| B-Cell Lymphoma | Phase 1 | China | 14 Mar 2022 | |
| B-cell lymphoma recurrent | Phase 1 | China | 14 Mar 2022 | |
| B-cell lymphoma refractory | Phase 1 | China | 14 Mar 2022 | |
| Pre B-cell acute lymphoblastic leukemia | Phase 1 | China | 14 Mar 2022 | |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | China | 14 Mar 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | Metastatic Colorectal Carcinoma Second line | 60 | (qroxcbpauv) = xgdjxdwnsh zdgepvluwz (iqszsfuzsi ) View more | - | 20 May 2013 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free